Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
28.13
-0.52 (-1.82%)
At close: Sep 5, 2025, 4:00 PM
28.50
+0.37 (1.32%)
After-hours: Sep 5, 2025, 5:29 PM EDT
Apellis Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Cash & Equivalents | 370.04 | 411.29 | 351.19 | 551.8 | 640.19 | 565.78 | Upgrade |
Short-Term Investments | 4.75 | 4.85 | 4.35 | 6.51 | 61.04 | 311.87 | Upgrade |
Cash & Short-Term Investments | 374.78 | 416.14 | 355.54 | 558.31 | 701.23 | 877.65 | Upgrade |
Cash Growth | 1.83% | 17.04% | -36.32% | -20.38% | -20.10% | 149.34% | Upgrade |
Accounts Receivable | 229.23 | 271.72 | 224.5 | 29.17 | 80.1 | 25 | Upgrade |
Other Receivables | - | - | - | 8.71 | - | - | Upgrade |
Receivables | 229.23 | 271.72 | 224.5 | 37.88 | 80.1 | 25 | Upgrade |
Inventory | 121.24 | 82.48 | 162.66 | 99.7 | 24 | - | Upgrade |
Prepaid Expenses | 13.47 | 9.51 | 8.59 | 7.18 | 5.17 | 3.4 | Upgrade |
Restricted Cash | 1.43 | 1.32 | 1.11 | 1.27 | 1.56 | 1.27 | Upgrade |
Other Current Assets | 15.47 | 7.78 | 13.93 | 15.18 | 11.98 | 9.88 | Upgrade |
Total Current Assets | 755.61 | 788.95 | 766.33 | 719.52 | 824.05 | 917.19 | Upgrade |
Property, Plant & Equipment | 16.75 | 19.04 | 21.09 | 24.9 | 26.08 | 24.52 | Upgrade |
Long-Term Accounts Receivable | - | - | - | 15 | 30 | 18 | Upgrade |
Other Long-Term Assets | 49.03 | 77.06 | 1.31 | 0.8 | 1.64 | 0.86 | Upgrade |
Total Assets | 821.39 | 885.05 | 788.73 | 760.22 | 881.77 | 960.57 | Upgrade |
Accounts Payable | 54.24 | 38.57 | 37.52 | 37.34 | 16.91 | 8.48 | Upgrade |
Accrued Expenses | 139 | 140.18 | 127.81 | 95.14 | 103.24 | 111.94 | Upgrade |
Current Portion of Leases | 7.42 | 6.75 | 6.44 | 5.63 | 4.12 | 3.69 | Upgrade |
Other Current Liabilities | - | - | 75.83 | 29.5 | 7.58 | 4.23 | Upgrade |
Total Current Liabilities | 200.66 | 185.51 | 247.59 | 167.61 | 131.85 | 128.33 | Upgrade |
Long-Term Debt | 454.04 | 452.83 | 93.03 | 92.74 | 189.02 | 358.83 | Upgrade |
Long-Term Leases | 8.31 | 10.2 | 11.45 | 14.35 | 17.08 | 15.22 | Upgrade |
Other Long-Term Liabilities | 2.08 | 7.97 | 242.13 | 315.65 | 345.15 | 253.64 | Upgrade |
Total Liabilities | 665.09 | 656.51 | 594.21 | 590.35 | 683.1 | 756.01 | Upgrade |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade |
Additional Paid-In Capital | 3,329 | 3,267 | 3,036 | 2,480 | 1,857 | 1,131 | Upgrade |
Retained Earnings | -3,170 | -3,035 | -2,837 | -2,309 | -1,657 | -926.35 | Upgrade |
Comprehensive Income & Other | -2.57 | -3.31 | -3.54 | -0.88 | -2.09 | -0.12 | Upgrade |
Total Common Equity | 156.31 | 228.54 | 194.52 | 169.87 | 198.66 | 204.56 | Upgrade |
Shareholders' Equity | 156.31 | 228.54 | 194.52 | 169.87 | 198.66 | 204.56 | Upgrade |
Total Liabilities & Equity | 821.39 | 885.05 | 788.73 | 760.22 | 881.77 | 960.57 | Upgrade |
Total Debt | 469.77 | 469.78 | 110.93 | 112.71 | 210.22 | 377.73 | Upgrade |
Net Cash (Debt) | -94.99 | -53.65 | 244.61 | 445.59 | 491.01 | 499.92 | Upgrade |
Net Cash Growth | - | - | -45.10% | -9.25% | -1.78% | 156.43% | Upgrade |
Net Cash Per Share | -0.76 | -0.43 | 2.06 | 4.20 | 5.82 | 6.65 | Upgrade |
Filing Date Shares Outstanding | 126.29 | 125.52 | 120.58 | 111.29 | 97.73 | 80.38 | Upgrade |
Total Common Shares Outstanding | 126.19 | 124.5 | 119.56 | 110.77 | 97.52 | 76.13 | Upgrade |
Working Capital | 554.95 | 603.45 | 518.74 | 551.91 | 692.2 | 788.87 | Upgrade |
Book Value Per Share | 1.24 | 1.84 | 1.63 | 1.53 | 2.04 | 2.69 | Upgrade |
Tangible Book Value | 156.31 | 228.54 | 194.52 | 169.87 | 198.66 | 204.56 | Upgrade |
Tangible Book Value Per Share | 1.24 | 1.84 | 1.63 | 1.53 | 2.04 | 2.69 | Upgrade |
Updated Jul 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.